Drugs Made In Stock Today

DMII Stock   10.00  0.02  0.20%   

Performance

Good

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Drugs Made is trading at 10.00 as of the 19th of February 2026. This is a 0.20 percent up since the beginning of the trading day. The stock's open price was 9.98. Drugs Made has only a 7 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 21st of November 2025 and ending today, the 19th of February 2026. Click here to learn more.
Business Domain
Financial Services
IPO Date
3rd of December 2025
Classification
Financials
Drugs Made is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 65.58 M outstanding shares of which 85.98 K shares are currently shorted by private and institutional investors with about 1.0 trading days to cover. More on Drugs Made In

Moving together with Drugs Stock

  0.86DNMX Dynamix IIIPairCorr

Moving against Drugs Stock

  0.47DB Deutsche Bank AGPairCorr
  0.45WLAC Willow Lane AcquisitionPairCorr
  0.45AAM AA Mission AcquisitionPairCorr
  0.34ETHM Dynamix Symbol ChangePairCorr
  0.33IPC Imperial Pacific Earnings Call TodayPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Drugs Stock Highlights

CEO BoardLynn Stockwell
Business ConcentrationDiversified Capital Markets, Financial Services, NASDAQ Composite, Financials, Capital Markets, Financial Services, Financial Services (View all Sectors)
Financial Strength
Drugs Made In (DMII) is traded on NASDAQ Exchange in USA and employs 1 people. Drugs Made is listed under Diversified Capital Markets category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 655.09 M. Drugs Made In conducts business under Capital Markets sector and is part of Financials industry. The entity has 65.58 M outstanding shares of which 85.98 K shares are currently shorted by private and institutional investors with about 1.0 trading days to cover.
Check Drugs Made Probability Of Bankruptcy
Ownership Allocation
Drugs Made holds a total of 65.58 Million outstanding shares. Drugs Made In shows significant amount of outstanding shares owned by insiders and institutional investors . Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Drugs Ownership Details

Drugs Made In Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Drugs Made market risk premium is the additional return an investor will receive from holding Drugs Made long position in a well-diversified portfolio.

Drugs Stock Against Markets

When determining whether Drugs Made In is a strong investment it is important to analyze Drugs Made's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Drugs Made's future performance. For an informed investment choice regarding Drugs Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Drugs Made In. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is there potential for Diversified Capital Markets market expansion? Will Drugs introduce new products? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Drugs Made listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Drugs Made In's market price often diverges from its book value, the accounting figure shown on Drugs's balance sheet. Smart investors calculate Drugs Made's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Drugs Made's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Drugs Made's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.